Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
AHCL system improves glycemic control in adults with T1DM
Last updated August 22, 2026
Key finding
Time spent with glucose levels in target range increased from 69.3% at baseline to 85.0% at 3 months in the AHCL group.
This study evaluated the MiniMed 780G advanced hybrid closed-loop system in adults with type 1 diabetes, showing significant improvements in glucose control and quality of life.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the MiniMed 780G advanced hybrid closed-loop system in adults with type 1 diabetes, showing significant improvements in glucose control and quality of life.
Clinical relevance
These findings are clinically significant as they suggest that the MiniMed 780G system can enhance diabetes management, potentially leading to better long-term health outcomes for individuals with type 1 diabetes. Improved glucose control can reduce the risk of diabetes-related complications, making this technology a valuable option for patients.
Keep in mind
Limited generalizability due to specific population characteristics. Short follow-up duration may not capture long-term effects. Potential biases in self-reported quality of life measures.
Published in
Journal Reference
Publication details and source links for this paper.
Bartłomiej M, Anna J, Beata K, et al. Outcomes of Transitioning to the MiniMed 780G Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes. Diabetes Care. 2022;45(11):2628-2635. doi:10.2337/dc22-0470
Main Effects
Time in target glucose range increased by 21.5% (p=0.001) in the AHCL group.
Time below range (<70 mg/dL) decreased by 4.4% (p=0.001) in the AHCL group.
HbA1c levels improved significantly in the AHCL group (p=0.005).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Hybrid closed-loop system, Multiple Daily Injections (MDI) and HbA1c, Quality of life, Time in range.
This study contributes evidence to
Primary intervention
Hybrid closed-loop system
Primary outcomes
- HbA1c
- Quality of life
- Time in range
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
962
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Insulin Delivery Systems and CGM Time in Range
Related evidence
Evidence relationship
Insulin Delivery Systems and HbA1c
Save evidence
Evidence relationship
Insulin Delivery Systems and Quality of Life Outcomes
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Quality of life
Hybrid closed-loop system → Quality of life
Hybrid closed-loop system → Quality of life
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 69
- generally_consistent
Supporting studies: Based on 17 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerQuality of life
Multiple Daily Injections (MDI) → Quality of life
Multiple Daily Injections (MDI) → Quality of life
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTime in range
Multiple Daily Injections (MDI) → Time in range
Multiple Daily Injections (MDI) → Time in range
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Participants in the AHCL group spent 21.5% more time in target glucose range.
- AHCL group experienced a 4.4% reduction in time below range.
- Significant improvement in HbA1c levels for the AHCL group.
Who this applies to
- Adults aged 18 and older with type 1 diabetes.
- Individuals currently managing diabetes with insulin therapy.
Keep in Mind
- Results may not apply to younger populations or those with type 2 diabetes.
- The study's short duration limits understanding of long-term benefits.
- Self-reported outcomes may introduce bias in quality of life assessments.
Between the Lines
- Limited generalizability due to specific population characteristics.
- Short follow-up duration may not capture long-term effects.
- Potential biases in self-reported quality of life measures.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Devices & Technology
Insulin Delivery Systems → CGM Time in Range
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 69
- generally_consistent
Supporting studies: Based on 17 studies
View evidenceDevices & Technology
Insulin Delivery Systems → HbA1c
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 7 studies
View evidenceDevices & Technology
Insulin Delivery Systems → Quality of Life Outcomes
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
CGM Time in Range Evidence Hub
All studies measuring CGM Time in Range
17 studies
outcome_hubMeasures CGM Time in Range as a key outcome.
Insulin Delivery Systems Evidence Hub
All studies on Insulin Delivery Systems
17 studies
intervention_hubContributes to Insulin Delivery Systems evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
7 studies
outcome_hubMeasures HbA1c as a key outcome.
Quality of Life Outcomes Evidence Hub
All studies measuring Quality of Life Outcomes
3 studies
outcome_hubMeasures Quality of Life Outcomes as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Hybrid closed-loop system and Time in range
Intervention: Hybrid closed-loop systemOutcome: Time in range
17 results
All studies on Hybrid closed-loop system and HbA1c
Intervention: Hybrid closed-loop systemOutcome: HbA1c
7 results
All studies on Hybrid closed-loop system
Intervention: Hybrid closed-loop system
17 results
All studies measuring Time in range
Outcome: Time in range
17 results
All studies measuring HbA1c
Outcome: HbA1c
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Delivery Systems improve cgm time in range?
Strong Evidence
Insulin Delivery Systems may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Time in range
EvidenceScore™ Strong | EvidenceScore™ 87.9 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems improve HbA1c?
Strong Evidence
Insulin Delivery Systems appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 16 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems improve quality of life outcomes?
Strong Evidence
Insulin Delivery Systems may improve Quality of Life Outcomes.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Quality of life
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Multiple Daily Injections (MDI) improve HbA1c?
Moderate Evidence
Current evidence does not show a clear benefit of Multiple Daily Injections (MDI) for HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Closed-loop therapy may improve sleep quality in young people with T1DAutomated insulin-glucagon delivery reduces hypoglycemia riskClosed-loop therapy enhances glycemic control in type 2 diabetes.Hybrid Closed-Loop Insulin Improves Glycemic Control in YouthAHCL therapy improves glucose levels but increases diabetes distress in youth
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.